POTENTIAL CONFLICTS OF INTEREST: Dr Anagnostou has provided consultation to Roche Pharmaceuticals, Takeda Pharmaceutical Company, SynapDx and Quadrant Biosciences and received funding from Roche Pharmaceuticals, SynapDx, Sanofi-Aventis; in-kind support from AMO Pharmaceuticals; editorial stipends from John Wiley and Sons; and book royalties from APPI Energy and Springer. Dr Veenstra-VanderWeele has consulted or served on an advisory board for Roche Pharmaceuticals, Novartis, and SynapDx and received research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, and Forest and an editorial stipend from Springer and John Wiley and Sons; the other authors have indicated they have no potential conflicts of interest to disclose.